YEŞİLBAŞ, OsmanYozgat, Can YilmazAKINCI, NURVERSÖNMEZ, ŞİRİNTEKİN, ESERTALEBAZADEH, FARAZJAFAROV, UZEYİROTÇU TEMUR, HafizeYOZGAT, YILMAZ2021-08-242021-08-242021-09-01YEŞİLBAŞ O., Yozgat C. Y. , AKINCI N., SÖNMEZ Ş., TEKİN E., TALEBAZADEH F., JAFAROV U., OTÇU TEMUR H., YOZGAT Y., -Acute Myocarditis and Eculizumab Caused Severe Cholestasis in a 17-Month-Old Child Who Has Hemolytic Uremic Syndrome Associated with Shiga Toxin-Producing Escherichia coli-, JOURNAL OF PEDIATRIC INTENSIVE CARE, cilt.10, sa.3, ss.216-220, 2021http://hdl.handle.net/20.500.12645/29269Cardiovascular involvement is uncommon in pediatric patients with hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC-HUS). In this case report we presented a case of 17-month-old toddler who had a sporadic type of STEC-HUS complicated by acute myocarditis. The patient was successfully treated by a single dose of eculizumab after six doses of therapeutic plasma exchange (TPE) were inefficient to prevent the cardiac complication. Hepatotoxicity was observed after a single dose of eculizumab. Hepatic and cholestatic enzyme levels slowly returned to normal within 6 months. To the best of our knowledge, this is the first case of myocarditis/cardiomyopathy treated with eculizumab in STEC-HUS. This case illustrates the need for vigilance regarding myocardial involvement and eculizumab-induced hepatotoxicity in STEC-HUS.info:eu-repo/semantics/openAccessArticleWOS:00068310140000810.1055/s-0040-171311134395040